摘要
目的探讨齐拉西酮治疗精神分裂症的疗效和不良反应及其与对照药的差异。方法应用Meta分析对14项研究齐拉西酮与其它抗精神病药治疗精神分裂症对照研究的文献进行再分析,评价其合并效应量的大小和综合显著性检验。结果齐拉西酮治疗前后的自身对照,合并效应量d=3.52,95%CI为(2.86,4.18),综合显著性检验χ2=108.78,P<0.01,提示齐拉西酮治疗精神分裂症前后症状学变化有非常显著性差异,效应极强。齐拉西酮与对照药物在第2周末和治疗后组间的比较,提示齐拉西酮与对照组疗效相当,没有显著性差异。齐拉西酮组的恶心呕吐比对照组药多,有显著性差异(P<0.01),齐拉西酮组的锥体外系、体重增加不良副反应比对照组药少,有显著性差异(P<0.01),其他副反应无统计学意义。结论齐拉西酮与对照药的疗效无显著性差异,副反应各不相同。
Objective To study the efficacy and side effects of ziprasldone in treatment of patients with schizophrenia. Methods A total of 14 comparative studies of ziprasidone and the other antipsychotics in the treatment of patients with schizophrenia were analyzed by meta-analysis in therapeutic effects and side effects. Results The significant difference in symptoms between before and after treatment with ziprasidone was found （d =3.52,95%CI （2.86,4.18）, Χ^2=108. 78,P〈0.01）. Comparison between ziprasidone and the other antipsychotics at 2nd weekend after treatment and at the end of trials showed that there was no significant difference with respect to the clinical efficacy. The occurent rate of nausea and vomit in ziprasidone group was significantly higher than that in the other antipsychotics group , but the rates of weight gain and EPS were lower in ziprasidone group. Conclusion Ziprasidone has a similar clinical efficacy comparing with controlled antipsychotits.
出处
《精神医学杂志》
2008年第3期201-203,共3页
Journal of Psychiatry
